Peptides DB
Research-centric peptide and protocol reference hub
Study 26 of 40VIP (Vasoactive Intestinal Polypeptide) literatureExperimental eye research · Observational2026

Vasoactive intestinal peptide attenuates form-deprivation myopia in guinea pigs by suppressing the Wnt/β-catenin pathway along the retina-choroid-scleral axis.

VIP appears to influence myopia progression in guinea pigs by affecting the Wnt/β-catenin signaling pathway, but its relevance to human treatment is unclear.

Read at Experimental eye researchAdd to compare

Where it sits

this study against the rest of the vip (vasoactive intestinal polypeptide) corpus
8
Preclinical
25
Observational · this one
1
Open-label
2
Randomised
4
Reviews

Summary and findings

This study investigated the effect of intravitreal vasoactive intestinal peptide (VIP) on form-deprivation myopia (FDM) in guinea pigs, assessing a range of doses from 0.1 to 10000 pmol. The study found that VIP administration resulted in a dose-dependent response in both refractive error and axial length. Histological analysis indicated that VIP treatment suppressed the Wnt/β-catenin signaling pathway.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Experimental eye research supplied them

<h4>Purpose</h4>To investigate whether intravitreal vasoactive intestinal peptide (VIP) attenuates form-deprivation myopia (FDM) in a dose-dependent manner in guinea pigs and to determine whether this effect is mediated through regulation of the scleral Wnt/β-catenin signaling pathway.<h4>Methods</h4>A customized latex-balloon facemask was used to induce monocular FDM by covering the right eye, with the left eye remaining uncovered and serving as an internal self-control (SC). Fifty-four 3-week-old guinea pigs were randomly assigned to FDM without injection, FDM with intravitreal VIP (six subgroups receiving 0.1-10000 pmol VIP), or FDM with intravitreal saline. Refraction and axial length were measured at baseline and at weeks 2 and 4 to establish dose-response relationships and identify the optimal VIP concentration. Using the same FDM protocol, 45 additional 3-week-old guinea pigs were allocated to three groups: FDM, FDM + intravitreal VIP (100 pmol), and FDM + saline. Ocular biometric measurements were obtained at baseline and at weeks 2 and 4 during follow-up. Eyes were then enucleated for hematoxylin-eosin histological analysis of the retina, choroid, and sclera, as well as immunohistochemical assessment of β-catenin expression. Primary scleral fibroblasts were isolated to evaluate VIP-induced changes in Wnt3 and β-catenin expression using immunofluorescence and qRT-PCR.<h4>Results</h4>Both refractive error and axial length demonstrated a clear VIP dose-dependent response. Form deprivation induced aberrant activation of the scleral Wnt/β-catenin signaling pathway, which was significantly suppressed by VIP treatment. Moreover, VIP administration partially restored the disrupted collagen fibril organization characteristic of myopic sclera.<h4>Conclusions</h4>VIP effectively slows the progression of FDM by downregulating aberrant Wnt/β-catenin signaling.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the VIP (Vasoactive Intestinal Polypeptide) corpus

DClinical update: Assessment and management of Helicobacter pylori infection.BMJ (Clinical research ed.) · 2026reviewCGlycine transporter 1 inhibitor, bitopertin, changes excitatory and inhibitory network connectivity in mouse medial prefrontal cortex.Neuropharmacology · 2026 · Not reported in abstract.AnimalBComposite pheochromocytoma-ganglioneuroma secreting vasoactive intestinal peptide.Endocrinology, diabetes & metabolism case reports · 2026 · Maximal SUV of 14.4.HumanBOral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.Nature medicine · 2026HumanBVagal cholinergic denervation of the gastric mucosa in Long-COVID-19: In vivo evidence of structural autonomic dysfunction.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026 · 2.1 nm/µm³ vs 3.9 nm/µm³ in fundus, P < 0.01HumanCLiangfu Pill Alleviates Constipation-Predominant Irritable Bowel Syndrome through Modulation of 5-HT Signaling Pathway and Gut Microbiota.Chinese journal of integrative medicine · 2026 · P<0.05 or P<0.01 for various measured outcomes.Animal